Business Context and Reporting Period
This Form 8-K is filed by Frequency Therapeutics, Inc. (noting a discrepancy in the request metadata which listed "Korro Bio, Inc."). The report covers the quarter ended June 30, 2021, with the filing date and date of the earliest event reported as August 12, 2021. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. Consequently, the text of this 8-K does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for specific numerical metrics.
Material Changes
The filing announces the release of financial results for the quarter ended June 30, 2021, and provides operational updates. No specific quantitative material changes are detailed within the body of this 8-K text.
Guidance, Outlook, and Risks
- Operational Updates: The company provided operational updates alongside its financial results.
- Regulation FD Disclosure: The company posted an updated corporate slide presentation on its website (www.frequencytx.com) as Exhibit 99.2.
- Legal Status of Information: Information in Items 2.02 and 7.01, including the press release and slide deck, is furnished and not filed for purposes of Section 18 of the Exchange Act. The company undertakes no obligation to update or amend the slide presentation materials.
Investor Verification Checklist
- Verify the correct registrant name is Frequency Therapeutics, Inc. (Ticker: FREQ), not Korro Bio, Inc.
- Review Exhibit 99.1 (Press Release) for specific Q2 2021 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Corporate Slide Presentation) for updated operational milestones and pipeline status.
- Confirm the company's status as an Emerging Growth Company and its election regarding extended transition periods for accounting standards.